FDC receives FDA approval for Timolol Maleate Ophthalmic Solution
FDC Ltd. has received approval from the FDA for its Abbreviated New Drug Application (ANDA) for Timolol Maleate Ophthalmic Solution. Timolol Maleate Ophthalmic Solution is a nonselective beta-blocking drug, used as a primary line of treatment for glaucoma.
- FDA approves Hi-Tech Pharmacal’s generic ophthalmic solution
- Akorn gets FDA nod for generic Ophthalmic Solution
- CHMP recommends Azarga for approval
- FDA nod to Akorn’s Akten™ Ophthalmic Gel 3.5%
